Posted by Michael Wonder on 07 Dec 2020
Janssen seeks EU approval for twice yearly schizophrenia treatment
7 December 2020 - Janssen has submitted a marketing authorisation extension application to the EMA for paliperidone palmitate six monthly as a maintenance treatment for adults living with schizophrenia.
In particular, Janssen is seeking approval for the twice-yearly regimen in adult patients with schizophrenia who are already clinically stable on paliperidone palmitate one monthly or three monthly injectable products.
